In addition to Ozoralizumab, other therapies for cancer treatment, such as caplacizumab, a nanobody targeting von Willebrand factor (VWF), have been investigated for their efficacy in treating acquired thrombotic thrombocytopenic purpura (aTTP) [156,157]. This evidence concerns the gene VWF and acquired thrombotic thrombocytopenic purpura.